Glepaglutide
Overview
Glepaglutide is a long-acting GLP-2 receptor agonist peptide developed for the treatment of short bowel syndrome. GLP-2 promotes intestinal growth, enhances nutrient and fluid absorption, and reduces gastric secretion, thereby improving intestinal function in patients with compromised bowel length. The compound is administered subcutaneously to sustain therapeutic effects over extended intervals.
Key Research Findings
Phase 3 trials in adults with short bowel syndrome have demonstrated reductions in the volume of parenteral support required, with results published in gastroenterology journals in 2020 and 2021. The safety profile was generally favorable, with injection-site reactions and gastrointestinal symptoms being most common. Regulatory submissions are under consideration in multiple regions.
Subcutaneous injection
In Clinical Trials
Interested in Glepaglutide?
Find a verified provider experienced with Glepaglutide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Glepaglutide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.